Urinary incontinence refers to the involuntary leakage of urine. Factors such as increased body mass index, diabetes, pregnancy, and childbirth are linked with a higher risk of developing urinary incontinence. Studies indicate that around 24% to 45% of women experience urinary incontinence, with 9% to 39% of older women (aged over 60) reporting this condition on a daily basis. Thus, the increasing incidence of urinary incontinence is fuelling the demand for innovative drug solutions. Moreover, the introduction of novel drug delivery systems is expected to improve the efficacy and compliance of urinary incontinence treatments in the coming years.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to urinary incontinence.
There are several types of urinary incontinence: mixed, stress, functional, urge, and overflow incontinence. Treatments for urinary incontinence vary depending on the type, severity, and underlying cause. Anticholinergics such as oxybutynin and tolterodine are recommended for overactive bladder to relax the bladder muscles. Topical estrogen is often prescribed to postmenopausal women to improve bladder control. Further, there is a growing R&D investment in novel compounds, biologics, and personalized medicine that can effectively treat urinary incontinence.
Sponsored by Cook MyoSite, the objective of this double-blind randomized Phase III study is to compare the efficacy and safety of the autologous muscle derived cells for urinary sphincter repair (AMDC-USR; generic name: iltamiocel) with placebo in around 96 female participants with persistent or recurrent stress urinary incontinence post-surgical treatment.
This product will be delivered within 3-5 business days.
Report Coverage
The Urinary Incontinence Drug Pipeline Insight Report by the publisher gives comprehensive insights into urinary incontinence drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for urinary incontinence. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The urinary incontinence pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from urinary incontinence.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to urinary incontinence.
Urinary Incontinence Drug Pipeline Outlook
Urinary incontinence is a loss of bladder control that causes the unintentional passing of urine. In the United Kingdom, it is estimated that 34% of women are affected by urinary incontinence and more than 2 million men experience the condition. Urinary incontinence is associated with an increased risk of hospital acquired urinary tract infections, pressure ulcers, and skin infections, among others.There are several types of urinary incontinence: mixed, stress, functional, urge, and overflow incontinence. Treatments for urinary incontinence vary depending on the type, severity, and underlying cause. Anticholinergics such as oxybutynin and tolterodine are recommended for overactive bladder to relax the bladder muscles. Topical estrogen is often prescribed to postmenopausal women to improve bladder control. Further, there is a growing R&D investment in novel compounds, biologics, and personalized medicine that can effectively treat urinary incontinence.
Urinary Incontinence - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of urinary incontinence drugs based on several segmentations including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Small Molecules
- Biologics
- Cell Therapies
- Gene Therapies
By Route of Administration
- Oral
- Parenteral
- Others
Urinary Incontinence - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for urinary incontinence.Urinary Incontinence - Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the urinary incontinence pipeline analysis include small molecules, biologics, cell therapies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for urinary incontinence.Urinary Incontinence Clinical Trials Therapeutic Assessment - Competitive Dynamics
The report for the urinary incontinence drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in urinary incontinence clinical trials:- Versameb AG
- Cook MyoSite
- EG 427
- Elidah, Inc.
- Uromedica
- Amber Therapeutics Ltd
- Ethicon, Inc.
- Neuspera Medical, Inc.
Urinary Incontinence - Emerging Drugs Profile
Major drugs currently in the drug pipeline are as follows:
Biological: AMDC-USR (iltamiocel)Sponsored by Cook MyoSite, the objective of this double-blind randomized Phase III study is to compare the efficacy and safety of the autologous muscle derived cells for urinary sphincter repair (AMDC-USR; generic name: iltamiocel) with placebo in around 96 female participants with persistent or recurrent stress urinary incontinence post-surgical treatment.
Drug: VMB-100
Versameb AG is conducting a Phase II clinical trial to evaluate the investigational drug VMB-100, an mRNA encoding for IGF-1, for the treatment of moderate stress urinary incontinence. The study has enrolled an estimated 30 female subjects and is expected to be completed by November 2027.Reasons To Buy This Report
The Urinary Incontinence Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for urinary incontinence. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within urinary incontinence pipeline insights.Key Questions Answered in the Urinary Incontinence - Pipeline Insight Report
- What is the current landscape of urinary incontinence pipeline drugs?
- How many companies are developing urinary incontinence drugs?
- How many phase III and phase IV drugs are currently present in urinary incontinence pipeline drugs?
- Which companies/institutions are leading the urinary incontinence drug development?
- What is the efficacy and safety profile of urinary incontinence pipeline drugs?
- What are the opportunities and challenges present in the urinary incontinence drug pipeline landscape?
- Which company is conducting major trials for urinary incontinence drugs?
- What geographies are covered for urinary incontinence clinical trials?
- What are emerging trends in urinary incontinence clinical trials?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Urinary Incontinence
4 Patient Profile: Urinary Incontinence
5 Urinary Incontinence: Epidemiology Snapshot
6 Urinary Incontinence: Market Dynamics
7 Urinary Incontinence: Key Facts Covered
8 Urinary Incontinence, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Urinary Incontinence Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Urinary Incontinence Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Urinary Incontinence Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Urinary Incontinence Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Urinary Incontinence, Key Drug Pipeline Companies
